LH · 8-K · 20261028PR000213

Guidance / Outlook

LABCORP HOLDINGS INC. · 2026-10-28 · Importance 74 · Surprise 68 · Contradicted

Labcorp raised its 2026 enterprise revenue growth guidance to 5.9%–6.7%, from 5.4%–6.3%, and adjusted EPS guidance to $18.30–$18.70, from $18.10–$18.55. Updated revenue guidance is $14.779–$14.887 billion for the enterprise, $11.475–$11.551 billion for Diagnostics Laboratories, and $3.328–$3.358 billion for Biopharma Laboratory Services. Free cash flow guidance remained $1.240–$1.360 billion. Guidance assumes foreign exchange rates effective September 30, 2026, and includes anticipated capital allocation, including acquisitions, share repurchases, and dividends.

Key facts

• Labcorp raised full-year 2026 enterprise revenue growth guidance to 5.9%–6.7%, 50 basis points higher at the midpoint. source
• Labcorp’s updated 2026 enterprise revenue guidance is $14,779 million–$14,887 million, with growth guidance of 5.9%–6.7%. source
• Labcorp’s updated 2026 Diagnostics Laboratories revenue guidance is $11,475 million–$11,551 million, with growth guidance of 5.5%–6.2%. source
• Labcorp’s updated 2026 Biopharma Laboratory Services revenue guidance is $3,328 million–$3,358 million, with growth guidance of 7.4%–8.4%. source
• Labcorp’s updated 2026 free cash flow guidance is $1,240 million–$1,360 million. source
• Labcorp raised full-year 2026 adjusted EPS guidance to $18.30–$18.70, 18 cents higher at the midpoint. source
• Labcorp’s 2026 updated Biopharma Laboratory Services guidance includes a 1.3% impact from foreign currency translation. source
• Labcorp’s 2026 updated enterprise revenue guidance includes a 0.3% impact from foreign currency translation. source

Impact estimates